- 新癌症治疗法 -
The field of biologic drug development for cancer therapies has been greatly energized by the broad spectrum of innovative approaches and their stunning success. The Novel Therapies for Cancer and Emerging Targets track at PEGS Europe will provide a comprehensive picture of the preclinical and clinical development of novel biotherapeutics against cancer, including bispecific, ADC and immunotherapy approaches. Recent results will be reviewed and analyzed to reveal insights into why some strategies fail while others prove to be successful. New approaches to making immunotherapies safer and more effective will be considered and latest clinical progress will be shared. A session dedicated to emerging targets will be featured.


Preliminary Agenda

NEW APPROACHES TO COMBINATION THERAPY

Empirical Determination of Optimal Combination Therapies Targeting Immunological Pathways
Michael Schmidt, PhD, Vice President of Antibody Discovery & Engineering, Compass Therapeutics

Design Clinical Trials with Combinations
Andres Gutierrez, MD, CMO, Oncolytics Biotech

IMMUNOCYTOKINES: CLINICAL APPLICATIONS, SUCCESSES TO DATE AND HURDLES TO BE OVERCOME

Clinical Approaches for Immunocytokine Therapy Based on Antibody and Cytokine Modifications.
Stephen D. Gillies, PhD, Founder & President & CEO, Provenance Biopharmaceuticals Corp.

Talk Title to be Announced
Karin Schilbach, PhD, Hematology/Oncology, University Children's Hospital, Tübingen  

Unexpected Effects of Directed Therapy on Immune Recognition of Cancer Cells
Mar Valés-Gómez, PhD, Spanish National Research Council, CSIC; Spanish National Center for Biotechnology  

NEW STRATEGIES FOR LEAD GENERATION

Affinity Modulation of Various Antibodies Using Universal Allosteric Switch Modules
Stefan Duebel, PhD, Professor & Head, iTUBS Innovationsgesellschaft Technical University Braunschweig

Recombinant Human B Cell Repertoires Enable Screening for Rare, Specific, and Natively Paired Antibodies
Saravanan Rajan, PhD, Scientist II, Antibody Discovery & Protein Engineering, MedImmune

NEW TARGETS AND STRATEGIES IN IMMUNOTHERAPY

Identification of Functional Antitumor Antibodies from Immunoglobulin Sequence Repertoires of Cancer Patients
Daniel Emerling, PhD, Senior Vice President, Research, Atreca, Inc.

Targeting the Intracellular Proteome: Antibodies with T-Cell Receptor-Like Specificity towards the MHC-Peptide Complex
Yoram Reiter, PhD, Professor and Head of the Laboratory of Molecular Immunology, Faculty of Biology, Technion-Israel Institute of Technology

Targeting p53 in Cancer Using T-Cell Receptor Mimic Antibodies
Demin Li, MBBS, MSc, PhD, University Research Lecturer, Senior Research Fellow, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford

CAR Expressing NK Cell-Based Immunotherapies
Prof. Dr. Ulrike Köhl, PhD, Head of Fraunhofer Institute of Cellular Therapeutics and Immunology (IZI); Director, Institute of Clinical Immunology, University and University Hospital of Leipzig; and

Director, Institute of Cellular Therapeutics, GMP Development Unit and Cellular Therapy Centre, Hannover Medical School (MHH)

Developing an ROR1 Bispecific T-Cell Engager for Treatment of Solid Tumors
Amit C. Nathwani, PhD, Professor, Haematology, University College London

TGFβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis
Daniele Tauriello, PhD, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English